Emily A Kibble

TL;DR: An overview of the recent advances made in understanding the role of each immunophilin family, cyclophilins, FK506 binding proteins (FKBPs) and parvulins in bacteria will be provided.

TL;DR: An overview of the structures of bacterial virulence enzyme targets involved in protein folding, peptidoglycan biosynthesis and cell wall modification are given and progress towards inhibitor design of these targets for the development of novel anti-virulence therapeutic agents is presented.

TL;DR: A review highlighting the growing research interest in developing anti-virulence therapies (AVTs) which are directed towards inhibiting virulence factors to prevent infection is presented in this paper, where it is hypothesized that this will impart a smaller selective pressure for the emergence of resistance in the pathogen and in the microbiome, thus avoiding AMR development to the antiinfective.

TL;DR: Co-crystallography experiments with recombinant B. pseudomallei Mip protein and Mip inhibitors, biochemical analysis and computational modelling were used to predict the efficacy of lead compounds for broad-spectrum activity against other pathogens, indicating that Mip is a novel antivirulence target that can be inhibited using small-molecule compounds that prove to be promising broad- spectrum drug candidates in vitro.

TL;DR: The Detroit 562 pharyngeal immortalized cell monolayer model is used to measure the rate of attachment to and invasion of N. meningitidis and N. gonorrhoeae into epithelial cells.